GoAI
Get started
American Shared Hospital Services logo

American Shared Hospital Services

AMS

AMEXHealthcareMedical - Care Facilities

Open in GoAI

Previous close

$1.51

−$0.0015 · -0.10%

Aug 21, 4:00 PM ET

AMS company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

67

Undervalued

Momentum

26

Weakening

Sentiment

53

Mixed

Risk resilience

34

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

American Shared Hospital Services specializes in leasing advanced radiosurgery and radiation therapy equipment to healthcare providers. The company offers Gamma Knife stereotactic radiosurgery systems, a non-invasive technology used to treat conditions such as malignant and benign brain tumors, arteriovenous malformations, and trigeminal neuralgia. They also facilitate financing for Leksell Gamma Knife units. Additionally, the firm operates proton beam radiation therapy centers in Orlando, Florida, and Long Beach, California. Customers further benefit from comprehensive support encompassing planning, installation, reimbursement guidance, and marketing strategies. As of December 31, 2021, their portfolio included 115 active Gamma Knife units across the United States, complemented by two units in South America (Lima, Peru, and Guayaquil, Ecuador), and one proton beam radiation therapy system. Established in 1980, American Shared Hospital Services maintains its headquarters in San Francisco, California.

Industry
Medical - Care Facilities
Sector
Healthcare
Headquarters
US
CEO
Craig K. Tagawa
Listed since
Jul 3, 1984
Employees
83

Market position

Day range

Current $1.51

52-week range

Current $1.51

Open
$1.53
Previous close
$1.5115
Volume
4.33K
0.02× average
Average volume
210.99K
Average daily volume
Market cap
10M USD
Beta
0.3
Market reference 1
50-day average
$1.493
+1.14% above average
200-day average
$1.7929
-15.78% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
33.11M USD
P/E (TTM)
-5.98×
P/B (TTM)
0.45×
P/S (TTM)
0.33×
EV / EBITDA
8.14×
Earnings yield
-11.12%
Free cash flow yield
-32.49%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
17.10%
Operating margin
-8.43%
Net margin
-5.83%
Return on equity
-6.46%
Return on assets
-2.80%
Return on invested capital
-3.38%

Financial health

Debt / equity
0.89×
Current ratio
0.76×
Altman Z-score
0.63
Piotroski F-score
4 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends49%28%6%-15%Gross margin, FY2021: 38.16%Gross margin, FY2022: 42.45%Gross margin, FY2023: 43.82%Gross margin, FY2024: 32.41%Gross margin, FY2025: 17.96%Operating margin, FY2021: 7.66%Operating margin, FY2022: 12.31%Operating margin, FY2023: 1.27%Operating margin, FY2024: -9.90%Operating margin, FY2025: -7.17%Net margin, FY2021: 1.10%Net margin, FY2022: 6.73%Net margin, FY2023: 2.86%Net margin, FY2024: 7.71%Net margin, FY2025: -5.53%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 38.16%. Gross margin FY2022 42.45%. Gross margin FY2023 43.82%. Gross margin FY2024 32.41%. Gross margin FY2025 17.96%. Operating margin FY2021 7.66%. Operating margin FY2022 12.31%. Operating margin FY2023 1.27%. Operating margin FY2024 -9.90%. Operating margin FY2025 -7.17%. Net margin FY2021 1.10%. Net margin FY2022 6.73%. Net margin FY2023 2.86%. Net margin FY2024 7.71%. Net margin FY2025 -5.53%.

Income trends

Revenue

28.08M USD-0.91%

Operating income

−2.01M USD+28.20%

Net income

−1.55M USD−3.74M USD
Income trends across reported periods31.45M USD19M USD6.54M USD−5.92M USDRevenue, FY2021: 17.63M USDRevenue, FY2022: 19.75M USDRevenue, FY2023: 21.33M USDRevenue, FY2024: 28.34M USDRevenue, FY2025: 28.08M USDOperating income, FY2021: 1.35M USDOperating income, FY2022: 2.43M USDOperating income, FY2023: 270K USDOperating income, FY2024: −2.81M USDOperating income, FY2025: −2.01M USDNet income, FY2021: 194K USDNet income, FY2022: 1.33M USDNet income, FY2023: 610K USDNet income, FY2024: 2.19M USDNet income, FY2025: −1.55M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 17.63M USD. Revenue FY2022 19.75M USD. Revenue FY2023 21.33M USD. Revenue FY2024 28.34M USD. Revenue FY2025 28.08M USD. Operating income FY2021 1.35M USD. Operating income FY2022 2.43M USD. Operating income FY2023 270K USD. Operating income FY2024 −2.81M USD. Operating income FY2025 −2.01M USD. Net income FY2021 194K USD. Net income FY2022 1.33M USD. Net income FY2023 610K USD. Net income FY2024 2.19M USD. Net income FY2025 −1.55M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue28.08M USD28.34M USD21.33M USD19.75M USD17.63M USD
Cost of goods sold23.04M USD19.16M USD11.98M USD11.36M USD10.9M USD
Gross profit5.04M USD9.19M USD9.34M USD8.38M USD6.73M USD
Selling, general, and administrative7.06M USD7.41M USD7.02M USD5.15M USD4.53M USD
Operating expenses7.06M USD11.99M USD9.07M USD5.95M USD5.38M USD
Interest income—248K USD426K USD87K USD—
Interest expense1.57M USD1.5M USD1.11M USD806K USD742K USD
Depreciation and amortization5.71M USD6.17M USD5.17M USD5.12M USD5.28M USD
Operating income−2.01M USD−2.81M USD270K USD2.43M USD1.35M USD
Net income−1.55M USD2.19M USD610K USD1.33M USD194K USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
27%
3 beats, 8 misses, 0 met estimates
Average EPS surprise
-364.11%
11 comparable reports
Latest EPS result
-0.07
Estimate -0.02 · Miss by 250.00%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.08-0.03-0.13-0.24Q2 '25MissQ2 '25MissQ3 '25BeatQ4 '25MissQ1 '26MissQ2 '26MissQ3 '26MissQ4 '26Estimate
Q2 2025, reported Apr 4, 2025: actual -0.2, estimate 0.01, surprise -2100.00%, Miss. Q2 2025, reported May 15, 2025: actual -0.1, estimate 0.04, surprise -350.00%, Miss. Q3 2025, reported Aug 13, 2025: actual -0.04, estimate -0.07, surprise +42.86%, Beat. Q4 2025, reported Nov 13, 2025: actual -0.003, estimate 0.02, surprise -112.90%, Miss. Q1 2026, reported Mar 31, 2026: actual -0.09, estimate 0.02, surprise -550.00%, Miss. Q2 2026, reported May 14, 2026: actual -0.09, estimate -0.01, surprise -800.00%, Miss. Q3 2026, reported Aug 13, 2026: actual -0.07, estimate -0.02, surprise -250.00%, Miss. Q4 2026, reported Nov 12, 2026: actual —, estimate 0.03, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates9.43M8.2M6.98M5.75MQ2 '25BeatQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26MissQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q2 2025, reported Apr 4, 2025: actual 9.07M USD, estimate 7.7M USD, surprise +17.78%, Beat. Q2 2025, reported May 15, 2025: actual 6.11M USD, estimate 8.63M USD, surprise -29.18%, Miss. Q3 2025, reported Aug 13, 2025: actual 7.07M USD, estimate 7.81M USD, surprise -9.46%, Miss. Q4 2025, reported Nov 13, 2025: actual 7.17M USD, estimate 8.78M USD, surprise -18.33%, Miss. Q1 2026, reported Mar 31, 2026: actual 7.73M USD, estimate 8.78M USD, surprise -11.98%, Miss. Q2 2026, reported May 14, 2026: actual 7.1M USD, estimate 6.87M USD, surprise +3.35%, Beat. Q3 2026, reported Aug 13, 2026: actual 8.43M USD, estimate 7.56M USD, surprise +11.51%, Beat. Q4 2026, reported Nov 12, 2026: actual —, estimate 8.53M USD, surprise —, Comparison unavailable.

AMS peers

National HealthCare Corporation logo

NHC

National HealthCare Corporation

$233.4

-1.41%

Perspective Therapeutics, Inc. logo

CATX

Perspective Therapeutics, Inc.

$3.30

+2.80%

Electromed, Inc. logo

ELMD

Electromed, Inc.

$39.45

-1.38%

Lineage Cell Therapeutics, Inc. logo

LCTX

Lineage Cell Therapeutics, Inc.

$1.08

0.00%

InfuSystem Holdings, Inc. logo

INFU

InfuSystem Holdings, Inc.

$12.21

+0.08%

Protalix BioTherapeutics, Inc. logo

PLX

Protalix BioTherapeutics, Inc.

$2.38

0.00%

ETFs holding AMS

Funds reporting this stock among their holdings, ordered by reported position size.

Schwab International Equity ETF logoSchwab International Equity ETFSCHF
Market value
65.77M
Weight
0.09%
AUM
69.7B USD
Expense ratio
0.03%
Price / 1D
$28.46+0.85%
State Street SPDR Portfolio Developed World ex-US ETF logoState Street SPDR Portfolio Developed World ex-US ETFSPDW
Market value
35.54M
Weight
0.08%
AUM
41.92B USD
Expense ratio
0.03%
Price / 1D
$52.02+0.79%
Schwab Fundamental International Large Company Index ETF logoSchwab Fundamental International Large Company Index ETFFNDF
Market value
11.52M
Weight
0.04%
AUM
26.15B USD
Expense ratio
0.25%
Price / 1D
$55.84+0.83%
GMO International Quality ETF logoGMO International Quality ETFQLTI
Market value
11.29M
Weight
3.80%
AUM
298M USD
Expense ratio
0.60%
Price / 1D
$27.96+0.90%
John Hancock Investments - Multifactor Developed International ETF logoJohn Hancock Investments - Multifactor Developed International ETFJHMD
Market value
2.26M
Weight
0.24%
AUM
971.55M USD
Expense ratio
0.39%
Price / 1D
$46.405+0.66%
State Street SPDR MSCI ACWI ex-US ETF logoState Street SPDR MSCI ACWI ex-US ETFCWI
Market value
1.82M
Weight
0.06%
AUM
2.88B USD
Expense ratio
0.30%
Price / 1D
$41.52+0.65%
State Street SPDR Portfolio Europe ETF logoState Street SPDR Portfolio Europe ETFSPEU
Market value
1.22M
Weight
0.16%
AUM
741.65M USD
Expense ratio
0.07%
Price / 1D
$57.325+0.75%
State Street SPDR MSCI EAFE Fossil Fuel Reserves Free ETF logoState Street SPDR MSCI EAFE Fossil Fuel Reserves Free ETFEFAX
Market value
727.28K
Weight
0.14%
AUM
512.34M USD
Expense ratio
0.20%
Price / 1D
$55.93+0.75%

Continue in GoAI

Research AMS

research.disclaimer